Protein expression of the Ets transcription factor Elf-1 in breast cancer cells is negatively correlated with histological grading, but not with clinical outcome

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1121-1125

  Gerloff, Alice ^a   Dittmer, Angela ^a   Oerlecke, Ilka ^a   Holzhausen, Hans Jürgen ^a   Dittmer, Jürgen ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Breast cancer; E26 transformation specific proteins; Elf 1; Grading; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TRANSCRIPTION FACTOR ELF 1;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL RATE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 80053167653     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1409     Document Type: Article

References (34)

1. Dittmer J and Nordheim A: Ets transcription factors and human disease. Biochim Biophys Acta 1377: F1-F11, 1998. (Pubitemid 28207050)
2. Seth A and Watson DK: ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478, 2005. (Pubitemid 41540623)
3. Foos G and Hauser C: The role of Ets transcription factors in mediating cellular transformation. In: Handbook of Experimental Pharmacology. Gossen M, Kaufmann J and Triezenberg SJ (eds). Vol. 166, Springer, Heidelberg, pp259-275, 2004.
4. Sementchenko VI and Watson DK: Ets target genes: past, present and future. Oncogene 19: 6533-6548, 2000. (Pubitemid 32108443)
5. Hollenhorst PC, Shah AA, Hopkins C and Graves BJ: Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 21: 1882-1894, 2007. (Pubitemid 47204928)
6. Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA and Graves BJ: DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet 5: e1000778, 2009.
7. Tootle TL and Rebay I: Post-translational modifications influence transcription factor activity: A view from the ETS superfamily. Bioessays 27: 285-298, 2005. (Pubitemid 40476491)
8. Oikawa T and Yamada T: Molecular biology of the Ets family of transcription factors. Gene 303: 11-34, 2003. (Pubitemid 36151767)
9. Walunas TL, Wang B, Wang CR and Leiden JM: Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice. J Immunol 164: 2857-2860, 2000. (Pubitemid 30148940)
10. Choi HJ, Geng Y, Cho H, Li S, Giri PK, Felio K and Wang CR: Differential requirements for the Ets transcription factor Elf-1 in the development of NKT cells and NK cells. Blood 117: 1880-1887, 2011.
11. Dittmer J: The Biology of the Ets1 Proto-Oncogene. Mol Cancer 2: 29, 2003.
12. Takai N, Miyazaki T, Nishida M, Shang S, Nasu K and Miyakawa I: Clinical relevance of Elf-1 overexpression in endometrial carcinoma. Gynecol Oncol 89: 408-413, 2003. (Pubitemid 36687784)
13. Takai N, Miyazaki T, Nishida M, Nasu K and Miyakawa I: The significance of Elf-1 expression in epithelial ovarian carcinoma. Int J Mol Med 12: 349-354, 2003.
14. Huang X, Brown C, Ni W, Maynard E, Rigby AC and Oettgen P: Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 107: 3153-3160, 2006.
15. Andrews PG, Kennedy MW, Popadiuk CM and Kao KR: Oncogenic activation of the human Pygopus2 promoter by E74-like factor-1. Mol Cancer Res 6: 259-266, 2008. (Pubitemid 351342414)
16. Bredemeier-Ernst I, Nordheim A and Janknecht R: Transcriptional activity and constitutive nuclear localization of the ETS protein Elf-1. FEBS Lett 408: 47-51, 1997. (Pubitemid 27216460)
17. Wang CY, Petryniak B, Thompson CB, Kaelin WG and Leiden JM: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science 260: 1330-1335, 1993. (Pubitemid 23231978)
18. Juang YT, Solomou EE, Rellahan B and Tsokos GC: Phos-phorylation and O-linked glycosylation of Elf-1 leads to its translocation to the nucleus and binding to the promoter of the TCR zeta-chain. J Immunol 168: 2865-2871, 2002. (Pubitemid 34211666)
19. Juang YT, Tenbrock K, Nambiar MP, Gourley MF and Tsokos GC: Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol 169: 6048-6055, 2002. (Pubitemid 35291713)
20. Lim K and Chang HI: O-GlcNAc inhibits interaction between Sp1 and Elf-1 transcription factors. Biochem Biophys Res Commun 380: 569-574, 2009.
21. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV and Sweep CG: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 21: 8506-8509, 2002. (Pubitemid 36054891)
22. Dittmer A, Hohlfeld K, Lutzkendorf J, Muller LP and Dittmer J: Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell Mol Life Sci 66: 3053-3065, 2009.
23. Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen HJ, Kantelhardt E, Krenkel S, Muller V, Sweep FC, Thomssen C and Dittmer J: Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res 67: 10694-10702, 2007. (Pubitemid 350145895)
24. Dittmer A, Vetter M, Schunke D, Span PN, Sweep F, Thomssen C and Dittmer J: Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem 281: 14563-14572, 2006. (Pubitemid 43855159)
25. Dittmer A and Dittmer J: Beta-actin is not a reliable loading control in Western blot analysis. Electrophoresis 27: 2844-2845, 2006. (Pubitemid 44160833)
26. Ronneburg H, Span PN, Kantelhardt E, Dittmer A, Schunke D, Holzhausen HJ, Sweep FC and Dittmer J: Rho GDP dissociation inhibitor α expression correlates with the outcome of CMF treatment in invasive ductal breast cancer. Int J Oncol 36: 379-386, 2010.
27. Hsu T, Trojanowska M and Watson DK: Ets proteins in biological control and cancer. J Cell Biochem 91: 896-903, 2004.
28. De Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C and Verreman K: The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766: 79-87, 2006. (Pubitemid 44202569)
29. Oikawa T: ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95: 626-633, 2004.
30. Kopp JL, Wilder PJ, Desler M, Kim JH, Hou J, Nowling T and Rizzino A: Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene. J Biol Chem 279: 19407-19420, 2004. (Pubitemid 38623374)
31. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A and Hassell JA: HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15: 1513-1525, 1997. (Pubitemid 27464644)
32. Oettgen P: Functional redundancy of Ets1 and Ets2. Blood 114: 934-935, 2009.
33. Lindemann RK, Braig M, Hauser CA, Nordheim A and Dittmer J: Ets2 and PKCepsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells. Biochem J 372: 787-797, 2003. (Pubitemid 36760392)
34. Crepieux P, Coll J and Stehelin D: The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crit Rev Oncog 5: 615-638, 1994.